30 Pharma Regulators,
One Reference Tool.

Most Anglophone and Commonwealth markets accept English-language CPP issued by the UK MHRA. This includes Nigeria, Kenya, Ghana, Uganda, Tanzania, Rwanda, South Africa, Zimbabwe, India, Pakistan and Bangladesh. GCC regulators including SFDA, MOHAP, MOPH and NHRA accept English without translation. Francophone Africa typically requires certified French translation. EU regulators accept the legalised CPP but expect supporting product literature in the local language.

Saudi Arabia operates NUPCO as the strongest centralised aggregator. Kuwait runs Central Medical Stores. Qatar centralises through Hamad Medical Corporation. UAE remains fragmented across emirate-level authorities (DHA, DOH, SEHA, plus federal MOHAP). In Africa, Kenya runs KEMSA, Tanzania uses MSD, Uganda uses NMS. France operates through GHT regional groupings, Germany through individual hospital tenders, Ireland through the HSE.

Strong, fast pathways exist with the UK MHRA, France (ANSM, ATU framework), Germany (BfArM individual import), Netherlands (CBG-MEB special import), Belgium (FAMHP medical need) and Ireland (HPRA exempt medicinal products). Saudi Arabia (SFDA), UAE (MOHAP, DHA) operate named patient routes for life-saving and rare-disease medicines. Most major African and Asian regulators have named patient frameworks, but documentation thresholds vary considerably.

EU regulators generally process within 12 to 18 months for national registration. GCC ranges 12 to 24 months by market. African regulators range 12 to 24 months for major markets, longer in some smaller jurisdictions. India and Pakistan typically 9 to 18 months. These are guideline ranges and depend on product class, dossier quality and current regulator backlog.

The GCC operates a Central Registration Procedure managed by the Executive Board. Approval through the central pathway provides registration in member states subject to each national authority adopting the central decision. In practice, most companies still pursue national registration alongside central, particularly with SFDA, MOHAP and MOPH, because pricing decisions, hospital tender entry and distribution licences are administered separately at national level.

As of 2026 AMA is operational with member-state ratifications progressing. Lead regulators participating in regional convergence include SAHPRA (South Africa), EDA (Egypt), DMP (Morocco), NAFDAC (Nigeria), PPB (Kenya), FDA Ghana, TMDA (Tanzania), Rwanda FDA and NDA (Uganda). AMA does not yet operate a single registration. Documentation harmonisation between the larger African regulators is improving year by year.

GCC markets generally enforce strict cold chain compliance with documented temperature monitoring throughout customs clearance: SFDA, MOHAP and MOPH all require continuous logs from origin to receiving warehouse. EU regulators enforce GDP standards with no derogations. South Africa and Kenya enforce strict documentation; smaller African markets sometimes lack reliable cold chain infrastructure on the receiving side, making forward-leaning shipper monitoring even more critical.